UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research

Fittall, Matthew; Liu, Justin; Platt, James; Ionescu, Maria; Sheehan, Remarez; Johal, Sukhmunni; Mew, Rosie; ... Lee, Lennard YW; + view all (2023) The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research. British Journal of Cancer , 128 (11) pp. 1977-1980. 10.1038/s41416-023-02251-9. Green open access

[thumbnail of s41416-023-02251-9.pdf]
Preview
PDF
s41416-023-02251-9.pdf - Published Version

Download (552kB) | Preview

Abstract

The COVID-19 pandemic has led to a range of novel and adaptive research designs. In this perspective, we use our experience coordinating the National COVID Cancer Antibody Survey to demonstrate how a balance between speed and integrity can be achieved within a hyper-accelerated study design. Using the COVID-19 pandemic as an example, we show this approach is necessary in the face of uncertain and evolving situations wherein reliable information is needed in a timely fashion to guide policy. We identify streamlined participant involvement, healthcare systems integration, data architecture and real-world real-time analytics as key areas that differentiate this design from traditional cancer trials, and enable rapid results. Caution needs to be taken to avoid the exclusion of patient subgroups without digital access or literacy. We summarise the merits and defining features of hyper-accelerated cancer studies.

Type: Article
Title: The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41416-023-02251-9
Publisher version: http://dx.doi.org/10.1038/s41416-023-02251-9
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10188887
Downloads since deposit
3Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item